Cytiva, a global life sciences leader, is investing in additional resins manufacturing operations outside of Sweden, with the acquisition of a new facility in Muskegon, MI. The new chromatography resins manufacturing site is part of Cytiva and Pall Corp.’s $1.5 billion capacity expansion investment.
 
Emmanuel Ligner, Danaher Group Executive and President and CEO of Cytiva, said, “This shows our leadership in action, strengthening our focus on providing customers who use our resins to manufacture vaccines and life-saving therapeutics.”
 
The site will include a 168,000 sq.-ft. biomanufacturing center consisting of multiple buildings. Cytiva will expand beyond Sweden to manufacture these resins, media that is critical in purifying and analyzing biomolecules for pharma and biopharmaceutical development of medicines. The facility will be home to approximately 200 associates when completed. Construction will begin 3Q22 and manufacturing is expected to begin in 2026.
 
“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible,” said Ligner. “By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”
 
The site also benefits from the support of the Michigan Economic Development Corporation (MEDC), the Michigan Strategic Fund (MSF), and a co-operative agreement funded through the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, With contracting support from the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the U.S. Army Contracting command (ACC).